LONDON, UK / ACCESSWIRE / November 9, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc ('Amryt') to its leadership team.
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
Early this month, medtech giant Baxter International revealed its plan to spin off its largest unit, kidney care, and indicated it was likely to do the same with some of its other business sectors. In the same release, the Illinois-based company also said it had accepted the resignation of Chief Operating Officer Giuseppe Accogli.
During a day of travel for many in biopharma ahead of this year's annual J.P. Morgan Healthcare Conference, Italy’s Chiesi Farmaceutici kicked off the week with a buyout.
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (Nasdaq: AMYT), a global, commercial-stage...
Amryt Pharmaceuticals`s Mycapssa (octreotide) Receives Approval in Europe
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors